Oracle buys goBalto, a study startup platform for faster clinical trials
Oracle is acquiring goBalto, a software platform that develops cloud-based solutions for drug trial sponsors and clinical research organizations. The terms of the deal were not disclosed. The acquisition would help Oracle expand its health Sciences business and accelerate clinical trials by streamlining and automating the selection and set up of the best performing clinical research sites to conduct trials.
Founded in Silicon Valley in 2008 by biotechnology industry veteran Jae Chung and backed by leading health technology investors, goBalto applies Agile and lean start-up methodologies to building technological solutions that address evolving global healthcare. goBalto’s study startup solutions are activated at over 90,000 research sites across 2,000+ studies in over 80 countries to deliver significant savings to customers with over 30% quantifiable reduction in study startup cycle times. goBalto is backed by a group of industry veterans that creates simple, focused software for the global drug trial industry. Their products offer drug trial sponsors and clinical research organizations the fastest, easiest possible way to start clinical studies on the web.
Oracle Health Sciences offers customers the industry’s most advanced cloud solution for clinical trial planning, data collection, trial execution and safety management. goBalto adds the leading industry cloud solution that significantly reduces clinical trial startup time. Together, Oracle and goBalto will provide the most complete end-to-end cloud platform dedicated to unifying action and accelerating results for the Life Sciences industry. The Oracle Cloud offers complete SaaS application suites for ERP, HCM and CX, plus best-in-class database Platform as a Service (PaaS) and Infrastructure as a Service (IaaS) from data centers throughout the Americas, Europe and Asia
“Clinical trial site selection and activation is one of the most manual and time-consuming processes for our customers,” said Steve Rosenberg, Senior Vice President and General Manager of Oracle Health Sciences Global Business Unit. “Oracle Health Sciences is designed to provide the industry with the best end-to-end clinical trial experience and the addition of goBalto will further allow our customers to remove another barrier from delivering treatments to patients faster.”
“We set out on a mission to streamline the clinical trial study startup process ten years ago because we saw how untenable it was for pharmaceutical companies and contract research organizations to track 1,000+ sites by 1,000+ specialists on spreadsheets,” said Jae Chung, Founder and President of goBalto.
“We are delighted to join forces with Oracle as the benefits offered to both our customers and employees as a broader clinical trial continuum are unparalleled in the industry,” said Sujay Jadhav, CEO of goBalto.